Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
暂无分享,去创建一个
Luca Laurenti | Raul Rabadan | Robin Foà | Hossein Khiabanian | Davide Rossi | Laura Pasqualucci | Giulia Fabbri | Jiguang Wang | L. Pasqualucci | R. Rabadán | R. Foà | Hossein Khiabanian | G. Fabbri | D. Rossi | G. Gaidano | R. Marasca | Jiguang Wang | V. Gattei | L. Laurenti | Gianluca Gaidano | Francesco Forconi | F. Forconi | Valter Gattei | Roberto Marasca | Giovanni Del Poeta | G. del Poeta
[1] James R. Downing,et al. Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells , 2010, Nature.
[2] Axel Benner,et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.
[3] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[4] A. Ashworth,et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. , 2012, Blood.
[5] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[6] C. Yau,et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia , 2012, Leukemia.
[7] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[8] A. Tsimberidou,et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .
[9] J. Carpten,et al. Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.
[10] K. Anderson,et al. Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.
[11] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[12] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[13] Camille Stephan-Otto Attolini,et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer , 2010, Proceedings of the National Academy of Sciences.
[14] T. Haferlach,et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.
[15] J. Gribben,et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.
[16] L. Pasqualucci,et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.
[17] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[18] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[19] D. Rossi,et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors , 2009, British journal of haematology.
[20] C. Maley,et al. Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .
[21] B. Parsons. Monoclonal tumor origin is an underlying misconception of the RESIC approach , 2011, Proceedings of the National Academy of Sciences.
[22] Michael Hallek,et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. , 2009, Blood.
[23] Raul Rabadan,et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.
[24] L. Medeiros,et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2013 .
[25] Y. Pekarsky,et al. NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.
[26] Raul Rabadan,et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome , 2013, The Journal of experimental medicine.
[27] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[28] Stavroula Ntoufa,et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients , 2011, Haematologica.
[29] Jenny Taylor,et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.
[30] S. Richards,et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. , 2008, The New England journal of medicine.
[31] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[32] A. Ashworth,et al. Whole genome sequencing of matched primary and metastatic acral melanomas. , 2012, Genome research.
[33] Marcos González,et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. , 2009, Blood.
[34] C. Nordling. A New Theory on the Cancer-inducing Mechanism , 1953, British Journal of Cancer.
[35] P. Ouillette,et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia , 2012, Genes, chromosomes & cancer.
[36] J. Byrd,et al. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study , 2012, Leukemia & lymphoma.
[37] T. Haferlach,et al. Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL , 2012, British journal of haematology.
[38] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[39] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] L. Pecciarini,et al. General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. , 2011, Blood.
[41] J. Carpten,et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.
[42] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[43] J. Salk. Clonal evolution in cancer , 2010 .
[44] Š. Pospíšilová,et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.
[45] Muriel Médard,et al. Network deconvolution as a general method to distinguish direct dependencies in networks , 2013, Nature Biotechnology.
[46] Luca Laurenti,et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL , 2012, Haematologica.
[47] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[48] Andrea Califano,et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.
[49] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[50] R. Dalla‐Favera,et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.
[51] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Trey Ideker,et al. Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..
[53] M. Dyer,et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] D. Catovsky,et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.
[55] M. Stratton,et al. A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.